Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Empagliflozin Fails to...

Empagliflozin Fails to Preserve Beta-Cell Function After Gestational Diabetes: Trial Finds

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-10-02T08:30:05+05:30  |  Updated On 2 Oct 2025 8:30 AM IST
Empagliflozin Fails to Preserve Beta-Cell Function After Gestational Diabetes: Trial Finds
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Canada: Empagliflozin did not significantly preserve beta-cell function in women with a recent history of gestational diabetes, according to a randomized, placebo-controlled trial published in Diabetes, Obesity and Metabolism. While the study did not show a clear benefit for beta-cell health, researchers observed signals suggesting the drug might help stabilize insulin sensitivity and fasting glucose, highlighting the need for larger, longer studies.

Led by Caroline K. Kramer of the Leadership Sinai Centre for Diabetes at Mount Sinai Hospital, Toronto, the trial addressed an important question: can early pharmacological intervention protect women with prior gestational diabetes mellitus (GDM) from progressing to type 2 diabetes? Women with a history of GDM are known to face a heightened risk of beta-cell decline and subsequent dysglycemia, yet few clinical trials have tested strategies to slow this process.
The double-blind study enrolled 91 participants between 6 and 36 months after childbirth. All had experienced GDM during pregnancy. They were randomly assigned to receive either 10 mg of the sodium–glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin or a placebo once daily for 48 weeks. Investigators used the Insulin Secretion-Sensitivity Index-2 (ISSI-2) derived from an oral glucose tolerance test to evaluate beta-cell function. Additional measures included the insulinogenic index/HOMA-IR and ΔC-peptide/Δglucose multiplied by the Matsuda index.
The study revealed the following findings:
  • After nearly a year of treatment, there was no significant difference in beta-cell function between the empagliflozin and placebo groups.
  • Baseline-adjusted ISSI-2 scores were 525 for the empagliflozin group and 560 for the placebo group, a nonsignificant difference.
  • Other indicators of beta-cell activity and insulin secretion showed similar results, confirming no meaningful preservation of beta-cell capacity with empagliflozin.
  • Rates of dysglycemia were comparable, affecting 65.7% of the empagliflozin group and 48.2% of the placebo group.
  • Only 9.4% of women on empagliflozin experienced worsening glucose tolerance compared with 28% in the placebo group, a trend approaching statistical significance.
The researchers pointed out that the relatively small sample size limited the trial’s power to detect subtle effects. They also emphasized that although the main beta-cell endpoint was negative, the data hinted at potential benefits in insulin sensitivity and fasting glucose trajectories among those taking empagliflozin.
"Given the persistent risk of type 2 diabetes in women with prior gestational diabetes, the findings underscore the importance of continued investigation. Larger, longer trials are needed to clarify whether SGLT-2 inhibitors like empagliflozin can play a preventive role in this high-risk population," the authors wrote.
"While empagliflozin did not demonstrate a protective effect on beta-cell function over 48 weeks, its favorable influence on glucose trends suggests it may warrant further evaluation as part of a broader strategy to reduce diabetes risk after gestational diabetes," they concluded.
Reference: https://doi.org/10.1111/dom.70146


Diabetes Obesity and Metabolismgestational diabetesEmpagliflozinbeta-cell function
Source : Diabetes, Obesity and Metabolism
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

    Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

    Pneumococcal Disease Risk and Vaccination in Cardiac Conditions: Indian Cardiologists Group Recommendations

    Pneumococcal Disease Risk and Vaccination in Cardiac Conditions: Indian Cardiologists' Group...

    Identifying Aspirin Candidates for Primary Prevention: Focus on Men Aged 40- 50 with Metabolic Syndrome and Cardiometabolic Risk

    Identifying Aspirin Candidates for Primary Prevention: Focus on Men Aged 40- 50 with Metabolic...

    Unlocking the Potential of Pharmacists for a Healthier India - Manjiri Gharat

    Unlocking the Potential of Pharmacists for a Healthier India - Manjiri Gharat

    Indias Growing Footprint in Global Research : Recognition, Reflection and the Road Ahead -  Dr (Prof) Raju Vaishya

    India's Growing Footprint in Global Research : Recognition, Reflection and the Road Ahead - Dr...

    View All

    Journal Club Today

    Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

    Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

    View All

    Health News Today

    Health Bulletin 01/October/2025

    Health Bulletin 01/October/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok